Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — Xoma — JP Morgan Conference 2006
20 slides from Xoma Royalty's conference presentation, Jan 10, 2006
Slide 1: A Leader in Therapeutic Antibodies
A Leader in Therapeutic Antibodies January 11, 2006 JP Morgan Conference Filed Pursuant to Rule 425 Registration No. 333-130441 January 10, 2006
Slide 2: Forward-Looking Statements
Statements made in this presentation relating to future financial performance or results, the timing of regulatory filings, the timing and results of clinical trials and other aspects of product development, collaborative and other strategic relationships, the regulatory process and approvals, colla
Slide 3: Registration statement and prospectus notice
XOMA, Ltd. has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents XOMA has filed with the SEC for more complete information abo
Slide 4: Premier Therapeutic Antibody Discovery and Development Company
Premier Therapeutic Antibody Discovery and Development Company Managing Development and Financial Risks, Effectively Utilizing Assets Marketed Product plus Diverse, Growing Pipeline XOMA “Right Place, Right Time, By Design”
Slide 5: Antibody Technologies
Antibody Technologies Antibody Technologies Comprehensive Antibody Platform for Comprehensive Antibody Platform for Discovery, Optimization and Manufacturing Discovery, Optimization and Manufacturing Multiple Antibody Phage Display Libraries Proprietary Human Engineering ™ Technology Bacterial Cell
Slide 6: Human Engineering Technology
XOMA Human Engineering™ Technology Clinically Validated 100% Success Rate To Date 25 mAbs Human Engineered™ 6 Different Targets Structural Approach Applicable to mAbs from any Species Issued IP Reduce Immunogenicity Reduce Immunogenicity of Non-human mAbs of Non-human mAbs
Slide 7: Therapeutic Antibody Development
Antibody Lead Discovery Preclinical Development Clinical Development Tech Dev Mfg Target Discovery Therapeutic Antibody Development Therapeutic Antibody Development Fully Integrated Development Infrastructure Fully Integrated Development Infrastructure Functional Biology Pharmacology (Efficacy, MOA)
Slide 8: Process Development and Manufacturing
Process Development Process Development Cell Line Development Cell Banking Pilot Plant Production Assay Development Formulation Development Manufacturing Manufacturing cGMP Production Scale to 2750 L - 3 Trains Grams to Kilograms 15,000 sq ft Pilot Plant GMP Manufacturing Plant XOMA’s Integrated Dev
Slide 9: xXoma
xXoma
Slide 10: Chiron XOMA
CHIRON XOMA xomra
Slide 11: XOMA Pipeline Highlights
Marketed Product Clinical-Stage Candidates Early-Stage Programs Technology Licenses Marketed Product RAPTIVA ® Plaque Psoriasis Genentech XOMA Pipeline Highlights RAPTIVA ® Atopic Dermatitis Genentech CHIR-12.12 CLL/MM Chiron rBPI / NEUPREX ® POHS, Burns, BMT Proprietary Clinical-Stage Candidates XM
Slide 12: RAPTIVA - Marketed Product
Genentech and Serono Large Markets with Unmet Need Moderate-to-Severe Plaque Psoriasis Large Safety and Efficacy Database Increasing Worldwide Sales Atopic Dermatitis Trial RAPTIVA ® - Marketed Product Quarterly RAPTIVA ® U.S. and Worldwide Sales Q1 Q2 Q3 Q4 Ex-U.S. U.S. 6.4 17.3 20.1 13.6 Q1 21.1 Q
Slide 13: CHIR 12.12 Anti-CD40 MAb
Phase I Testing in CLL and MM Underway B-cell Lymphoma/Leukemia Indications Anti-CD40 mAb High Affinity, Fully Human Dual Mechanism of Action Blocks CD40-CD40L-mediated Cancer Growth Recruits Immune Cells to Kill Tumors (ADCC) No Agonist or Stimulatory Activity Improved Efficacy Compared with Rituxa
Slide 14: rBPI / NEUPREX
Product Large Safety Database Potent Endotoxin Neutralization Multiple Indications POHS, Burns, BMT BioDefense - ARS Clinical Plan IST for POHS Underway Burns and BMT IST’s Soon EU Orphan Drug Application rBPI / NEUPREX ®
Slide 15: XMA005.2 Potent Anti-inflammatory mAb
Potent Anti-inflammatory mAb Multiple Indications RA, OA, Others Product Human Engineered™ High Affinity mAb – 300 fM Potent Inhibitory Activity Target Monthly Dosing Preclinical Stage Planned IND - Q406 Phase I - Q107 XMA005.2 -5000 XMA005.2 Target Challenge Unstimulated Antibody, nM In Vivo Inhibi
Slide 16: xXoma
xXoma
Slide 17: Pipeline Summary
Marketed Product RAPTIVA ® for Moderate-to-Severe Plaque Psoriasis Clinical Stage Programs RAPTIVA ® (Phase II) – Atopic Dermatitis CHIR-12.12 – CLL, MM rBPI /NEUPREX – POHS, Burns, BMT Growing Early-Stage Pipeline XMA005.2 Multiple Oncology Candidates Metabolic mAb Technology Licenses-related Produ
Slide 18: 2006 Catalysts
RAPTIVA ® – Market Penetration CMO Deals – NIAID, Cubist CIMZIA ™ and Lucentis ™ Royalty Possibilities CHIR-12.12 – Clinical Progress rBPI /NEUPREX – Additional IST’s Business Development Initiatives Registration / Exchange Offer for Convertible Debt Revenue Growth, Reductions in Spending and Cash B
Slide 19: xXoma
xXoma
Slide 20: Leader in Therapeutic Antibodies
A Leader in Therapeutic Antibodies * * *